Pacira BioSciences, Inc. Common Stock PCRX

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

• Zacks Investment Research 3 sept

  Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?

  Pacira (PCRX) reported Q2 2026 adjusted earnings of 73 cents per share, beating consensus estimates of 64 cents, with revenues of $192.4 million exceeding expectations. However, the company lowered its 2026 total revenue guidance to $735-$760 million from $745-$770 million following the divestiture of iovera to Zimmer Biomet. Despite the earnings beat, estimates have been trending downward, and the stock received a Zacks Rank #3 (Hold) rating with expectations for in-line returns.

  

• GlobeNewswire Inc. 22 jul

  Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026

  Pacira BioSciences announced it will report its second quarter 2026 financial results on August 4, 2026, followed by a live conference call and webcast at 4:30 p.m. ET. The company is a leader in non-opioid pain therapies with three commercial-stage treatments: EXPAREL, ZILRETTA, and iovera, plus a pipeline of clinical-stage assets including PCRX-201 in Phase 2 development for osteoarthritis.

  

• GlobeNewswire Inc. 8 jul

  Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Pacira BioSciences granted inducement equity awards to ten new employees on July 2, 2026, consisting of stock options for 9,200 shares and restricted stock units for 18,200 shares. The awards were approved by the People & Compensation Committee under Nasdaq Listing Rule 5635(c)(4) without stockholder approval.

  

• GlobeNewswire Inc. 15 jun

  Osteoarthritis Market Expected to Showcase Moderate Growth at a CAGR of 3% During the Forecast Period (2026–2036) Driven by Emerging Therapies and Rising Disease Burden | DelveInsight

  The osteoarthritis market is projected to grow at a 3% CAGR from 2026 to 2036, reaching USD 32.5 billion in 2025 across seven major markets. Growth is driven by an aging population, rising disease prevalence, and the launch of emerging therapies including LEVI-04, ZILOSUL, TissueGene-C, and AMZ001. Current treatment is dominated by opioids, but novel disease-modifying therapies and regenerative medicine approaches are expected to reshape the market landscape.